CancerNetwork articlesCancerNetwork articleshttps://www.cancernetwork.com/newsCancerNetwork articles© 2026 MJH Life Sciences™ and CancerNetwork. All rights reserved.Fri, 15 May 2026 01:41:19 +00005en-usCancerNetwork articles14447https://www.cancernetwork.com/newshttps://www.cancernetwork.com/logo.webp<![CDATA[How Does the Removal of Heparin Impact Safety in Oncology Care?]]>https://www.cancernetwork.com/view/how-does-the-removal-of-heparin-impact-safety-in-oncology-care-https://www.cancernetwork.com/view/how-does-the-removal-of-heparin-impact-safety-in-oncology-care-<![CDATA[Linda Chan, MSN, RN, ONC, CMSRN, EBP-C, emphasized that patients should check with providers regarding the removal of larger heparin lines for flushes.]]>Thu, 14 May 2026 23:00:00 GMTCancerNetworkusCancerNetwork Articles<![CDATA[TIP113 HERTHENA-PanTumor01 (NCT06172478): Expansion of a Global Phase 2 Trial of HER3-DXd in Patients With Advanced/Metastatic HR+/HER2− Breast Cancer]]>https://www.cancernetwork.com/view/tip113-herthena-pantumor01-nct06172478-expansion-of-a-global-phase-2-trial-of-her3-dxd-in-patients-with-advanced-metastatic-hr-her2-breast-cancerhttps://www.cancernetwork.com/view/tip113-herthena-pantumor01-nct06172478-expansion-of-a-global-phase-2-trial-of-her3-dxd-in-patients-with-advanced-metastatic-hr-her2-breast-cancer<![CDATA[]]>Thu, 14 May 2026 22:30:00 GMTCancerNetworkusCancerNetwork Articles<![CDATA[114 Comparing An AI-Based Prognostic Test With a 21-Gene Assay for Recurrence Prediction in Premenopausal Node-Positive HR+ HER2– Breast Cancer]]>https://www.cancernetwork.com/view/114-comparing-an-ai-based-prognostic-test-with-a-21-gene-assay-for-recurrence-prediction-in-premenopausal-node-positive-hr-her2-breast-cancerhttps://www.cancernetwork.com/view/114-comparing-an-ai-based-prognostic-test-with-a-21-gene-assay-for-recurrence-prediction-in-premenopausal-node-positive-hr-her2-breast-cancer<![CDATA[]]>Thu, 14 May 2026 22:00:00 GMTCancerNetworkusCancerNetwork Articles<![CDATA[Change in Flush Practice May Reduce Toxicity for Adult Patients With Cancer]]>https://www.cancernetwork.com/view/change-in-flush-practice-may-reduce-toxicity-for-adult-patients-with-cancerhttps://www.cancernetwork.com/view/change-in-flush-practice-may-reduce-toxicity-for-adult-patients-with-cancer<![CDATA[The incidence rate of occlusions per 1000 central line days was 10.68 in the pre-EBP change cohort and 21.00 in the post-EBP change cohort.]]>Thu, 14 May 2026 19:00:00 GMTCancerNetworkusCancerNetwork Articles<![CDATA[The Evolving Roles of MRD and Molecular Genotyping in Non-Hodgkin Lymphoma]]>https://www.cancernetwork.com/view/the-evolving-roles-of-mrd-and-molecular-genotyping-in-non-hodgkin-lymphomahttps://www.cancernetwork.com/view/the-evolving-roles-of-mrd-and-molecular-genotyping-in-non-hodgkin-lymphoma<![CDATA[Hua-Jay Cherng, MD, explored how ctDNA and MRD are shifting from theoretical markers to actionable clinical tools in DLBCL.]]>Thu, 14 May 2026 18:00:00 GMTCancerNetworkusCancerNetwork Articles<![CDATA[Breaking Silos: The Vital Role of Oncology Training Programs in Lymphoma]]>https://www.cancernetwork.com/view/breaking-silos-the-vital-role-of-oncology-training-programs-in-lymphomahttps://www.cancernetwork.com/view/breaking-silos-the-vital-role-of-oncology-training-programs-in-lymphoma<![CDATA[Hua-Jay Cherng, MD, described the “threefold” benefits of taking part in training programs among junior investigators in lymphoma.]]>Thu, 14 May 2026 14:00:00 GMTCancerNetworkusCancerNetwork Articles<![CDATA[Optimizing Therapeutic Strategies Across the NMIBC Paradigm]]>https://www.cancernetwork.com/view/optimizing-therapeutic-strategies-across-the-nmibc-paradigmhttps://www.cancernetwork.com/view/optimizing-therapeutic-strategies-across-the-nmibc-paradigm<![CDATA[]]>Thu, 14 May 2026 12:00:00 GMTCancerNetworkusCancerNetwork Articles<![CDATA[115 Evaluating an AI-Based Prognostic Test to Guide Adjuvant CDK4/6 Inhibitor Selection in Early HR+/HER2– Breast Cancer]]>https://www.cancernetwork.com/view/115-evaluating-an-ai-based-prognostic-test-to-guide-adjuvant-cdk4-6-inhibitor-selection-in-early-hr-her2-breast-cancerhttps://www.cancernetwork.com/view/115-evaluating-an-ai-based-prognostic-test-to-guide-adjuvant-cdk4-6-inhibitor-selection-in-early-hr-her2-breast-cancer<![CDATA[]]>Wed, 13 May 2026 22:30:00 GMTCancerNetworkusCancerNetwork Articles<![CDATA[116 Impact of Neoadjuvant Chemotherapy (NACT) Response on Clinical Outcomes With Ribociclib (RIB) in HR+/HER2− EBC: A Subgroup Analysis From the Phase 3 NATALEE Trial]]>https://www.cancernetwork.com/view/116-impact-of-neoadjuvant-chemotherapy-nact-response-on-clinical-outcomes-with-ribociclib-rib-in-hr-her2-ebc-a-subgroup-analysis-from-the-phase-3-natalee-trialhttps://www.cancernetwork.com/view/116-impact-of-neoadjuvant-chemotherapy-nact-response-on-clinical-outcomes-with-ribociclib-rib-in-hr-her2-ebc-a-subgroup-analysis-from-the-phase-3-natalee-trial<![CDATA[]]>Wed, 13 May 2026 22:00:00 GMTCancerNetworkusCancerNetwork Articles<![CDATA[FDA OKs Oral Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML]]>https://www.cancernetwork.com/view/fda-oks-oral-decitabine-cedazuridine-plus-venetoclax-in-newly-diagnosed-amlhttps://www.cancernetwork.com/view/fda-oks-oral-decitabine-cedazuridine-plus-venetoclax-in-newly-diagnosed-aml<![CDATA[Data from the phase 1/2 ASTX727-07 study support the FDA approval of decitabine plus cedazuridine and venetoclax in this AML population.]]>Wed, 13 May 2026 18:40:42 GMTCancerNetworkusCancerNetwork Articles<![CDATA[FDA Approves Sonrotoclax in Relapsed/Refractory Mantle Cell Lymphoma]]>https://www.cancernetwork.com/view/fda-approves-sonrotoclax-in-relapsed-refractory-mantle-cell-lymphomahttps://www.cancernetwork.com/view/fda-approves-sonrotoclax-in-relapsed-refractory-mantle-cell-lymphoma<![CDATA[Phase 1/2 findings from the BGB-11417-201 trial support the FDA approval of sonrotoclax in relapsed/refractory mantle cell lymphoma.]]>Wed, 13 May 2026 18:38:18 GMTCancerNetworkusCancerNetwork Articles<![CDATA[How Might CAR T Cells and Bispecifics Evolve in Multiple Myeloma Therapy?]]>https://www.cancernetwork.com/view/how-might-car-t-cells-and-bispecifics-evolve-in-multiple-myeloma-therapy-https://www.cancernetwork.com/view/how-might-car-t-cells-and-bispecifics-evolve-in-multiple-myeloma-therapy-<![CDATA[CAR T-cell therapies and bispecific antibodies are still in their infancy, according to Barry Paul, MD.]]>Wed, 13 May 2026 18:00:00 GMTCancerNetworkusCancerNetwork Articles<![CDATA[Novel Adenoid Cystic Carcinoma Drug Earns FDA Breakthrough Therapy Status]]>https://www.cancernetwork.com/view/novel-adenoid-cystic-carcinoma-drug-earns-fda-breakthrough-therapy-statushttps://www.cancernetwork.com/view/novel-adenoid-cystic-carcinoma-drug-earns-fda-breakthrough-therapy-status<![CDATA[Investigators are currently evaluating emiltatug ledadotin among patients with different solid tumors in a phase 1 trial.]]>Wed, 13 May 2026 16:00:00 GMTCancerNetworkusCancerNetwork Articles<![CDATA[Mitomycin Exhibits Sustained 36-Month Responses in LG-IR-NMIBC]]>https://www.cancernetwork.com/view/mitomycin-exhibits-sustained-36-month-responses-in-lg-ir-nmibchttps://www.cancernetwork.com/view/mitomycin-exhibits-sustained-36-month-responses-in-lg-ir-nmibc<![CDATA[The 36-month DOR rate was 64.5% among patients who achieved a 3-month CR with mitomycin for low-grade intermediate-risk non-muscle invasive bladder cancer.]]>Wed, 13 May 2026 15:30:00 GMTCancerNetworkusCancerNetwork Articles<![CDATA[The Unmet Needs in Oncology That Zedoresertib/Lunresertib Targets]]>https://www.cancernetwork.com/view/the-unmet-needs-in-oncology-that-zedoresertib-lunresertib-targetshttps://www.cancernetwork.com/view/the-unmet-needs-in-oncology-that-zedoresertib-lunresertib-targets<![CDATA[According to Timothy A. Yap, MBBS, PhD, FRCP, there is an unmet need in oncology for treating patients with CCNE1, FBXW7, and PPP2R1A genomic alterations.]]>Wed, 13 May 2026 14:00:00 GMTCancerNetworkusCancerNetwork Articles<![CDATA[Key Takeaways for Early Relapse Multiple Myeloma Management]]>https://www.cancernetwork.com/view/key-takeaways-for-early-relapse-multiple-myeloma-managementhttps://www.cancernetwork.com/view/key-takeaways-for-early-relapse-multiple-myeloma-management<![CDATA[]]>Wed, 13 May 2026 12:05:00 GMTCancerNetworkusCancerNetwork Articles<![CDATA[How TIL Therapy Provides Durable Responses in Refractory Melanoma]]>https://www.cancernetwork.com/view/how-til-therapy-provides-durable-responses-in-refractory-melanomahttps://www.cancernetwork.com/view/how-til-therapy-provides-durable-responses-in-refractory-melanoma<![CDATA[Muhammad Umair Mushtaq, MD, explains how TIL therapy offers a 30% response rate for patients with metastatic melanoma in whom prior treatments have failed.]]>Wed, 13 May 2026 12:00:00 GMTCancerNetworkusCancerNetwork Articles<![CDATA[Managing Comorbid Patients in Early Relapse Multiple Myeloma]]>https://www.cancernetwork.com/view/managing-comorbid-patients-in-early-relapse-multiple-myelomahttps://www.cancernetwork.com/view/managing-comorbid-patients-in-early-relapse-multiple-myeloma<![CDATA[]]>Wed, 13 May 2026 12:00:00 GMTCancerNetworkusCancerNetwork Articles<![CDATA[117 Risk of Recurrence (ROR) Among Patients With HR+/HER2− Early Breast Cancer (EBC) Involving 1-3 Axillary Lymph Nodes (N1): A Real-World Evaluation]]>https://www.cancernetwork.com/view/117-risk-of-recurrence-ror-among-patients-with-hr-her2-early-breast-cancer-ebc-involving-1-3-axillary-lymph-nodes-n1-a-real-world-evaluationhttps://www.cancernetwork.com/view/117-risk-of-recurrence-ror-among-patients-with-hr-her2-early-breast-cancer-ebc-involving-1-3-axillary-lymph-nodes-n1-a-real-world-evaluation<![CDATA[]]>Tue, 12 May 2026 22:30:00 GMTCancerNetworkusCancerNetwork Articles<![CDATA[118 Pooled Analysis of Patients Treated With 1st-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) in the MONALEESA (ML) Studies: Long-Term Progression-Free Survival (PFS)]]>https://www.cancernetwork.com/view/118-pooled-analysis-of-patients-treated-with-1st-line-1l-ribociclib-rib-endocrine-therapy-et-in-the-monaleesa-ml-studies-long-term-progression-free-survival-pfs-https://www.cancernetwork.com/view/118-pooled-analysis-of-patients-treated-with-1st-line-1l-ribociclib-rib-endocrine-therapy-et-in-the-monaleesa-ml-studies-long-term-progression-free-survival-pfs-<![CDATA[]]>Tue, 12 May 2026 22:00:00 GMTCancerNetworkusCancerNetwork Articles<![CDATA[How Is Zoldonrasib Different From Other Therapies in KRAS G12D+ NSCLC?]]>https://www.cancernetwork.com/view/how-is-zoldonrasib-different-from-other-therapies-in-kras-g12d-nsclc-https://www.cancernetwork.com/view/how-is-zoldonrasib-different-from-other-therapies-in-kras-g12d-nsclc-<![CDATA[Zoldonrasib has elicited good responses and progression-free survival in an area with a large unmet need, said Jonathan Wesley Riess, MD, MS.]]>Tue, 12 May 2026 19:00:00 GMTCancerNetworkusCancerNetwork Articles<![CDATA[Zoldonrasib Shows Promising Activity in KRAS G12D+ NSCLC]]>https://www.cancernetwork.com/view/zoldonrasib-shows-promising-activity-in-kras-g12d-nsclchttps://www.cancernetwork.com/view/zoldonrasib-shows-promising-activity-in-kras-g12d-nsclc<![CDATA[The safety profile of zoldonrasib appeared to be “superb” among patients with NSCLC harboring KRAS G12D mutations, said Jonathan Wesley Riess, MD, MS.]]>Tue, 12 May 2026 18:00:00 GMTCancerNetworkusCancerNetwork Articles<![CDATA[MYTHIC Trial Demonstrates Efficacy in Platinum-Resistant Ovarian Cancer]]>https://www.cancernetwork.com/view/mythic-trial-demonstrates-efficacy-in-platinum-resistant-ovarian-cancerhttps://www.cancernetwork.com/view/mythic-trial-demonstrates-efficacy-in-platinum-resistant-ovarian-cancer<![CDATA[Timothy A. Yap, MBBS, PhD, FRCP, presented data from the MYTHIC trial, demonstrating a 60% ORR at the RP2D in patients with CCNE1-amplified PROC.]]>Tue, 12 May 2026 17:00:00 GMTCancerNetworkusCancerNetwork Articles<![CDATA[Precision Medicine With Duvelisib and the Evolving Landscape of Lymphoma]]>https://www.cancernetwork.com/view/precision-medicine-with-duvelisib-and-the-evolving-landscape-of-lymphomahttps://www.cancernetwork.com/view/precision-medicine-with-duvelisib-and-the-evolving-landscape-of-lymphoma<![CDATA[Steven M. Horwitz, MD, discussed the PRIMO dosing strategy to manage adverse effects in lymphoma.]]>Tue, 12 May 2026 14:00:00 GMTCancerNetworkusCancerNetwork Articles<![CDATA[Selecting Among Preferred 1L Regimens — A Discussion]]>https://www.cancernetwork.com/view/selecting-among-preferred-1l-regimens-a-discussionhttps://www.cancernetwork.com/view/selecting-among-preferred-1l-regimens-a-discussion<![CDATA[New data show amivantamab+lazertinib boosts survival vs osimertinib in EGFR lung cancer, with Q4W subcutaneous dosing and side-effect tips.]]>Tue, 12 May 2026 12:05:00 GMTCancerNetworkusCancerNetwork Articles<![CDATA[Clinical Context & MARIPOSA Efficacy in 1L EGFRm NSCLC]]>https://www.cancernetwork.com/view/clinical-context-mariposa-efficacy-in-1l-egfrm-nsclchttps://www.cancernetwork.com/view/clinical-context-mariposa-efficacy-in-1l-egfrm-nsclc<![CDATA[New data show amivantamab plus lazertinib boosts survival and brain control in EGFR+ lung cancer, with convenient Q4W injection tips.]]>Tue, 12 May 2026 12:00:00 GMTCancerNetworkusCancerNetwork Articles<![CDATA[119 Progression-Free Survival (PFS) and Overall Survival (OS) Results From the Phase 3 MONALEESA-3 Trial of Postmenopausal Patients With Hormone Receptor–Positive (HR+)/Human Epidermal Growth Factor Receptor 2–Negative (HER2−) Advanced Breast Cancer (ABC) Treated With Ribociclib (RIB) + Fulvestrant (FUL): A Subgroup Analysis of Patients With Invasive Lobular Carcinoma (ILC)]]>https://www.cancernetwork.com/view/119-progression-free-survival-pfs-and-overall-survival-os-results-from-the-phase-3-monaleesa-3-trial-of-postmenopausal-patients-with-hormone-receptor-positive-hr-human-epidermal-growth-factor-receptor-2-negative-her2-advanced-breast-cancer-abc-treated-with-ribociclib-rib-fulvestrant-ful-a-subgroup-analysis-of-patients-with-invasive-lobular-carcinoma-ilc-https://www.cancernetwork.com/view/119-progression-free-survival-pfs-and-overall-survival-os-results-from-the-phase-3-monaleesa-3-trial-of-postmenopausal-patients-with-hormone-receptor-positive-hr-human-epidermal-growth-factor-receptor-2-negative-her2-advanced-breast-cancer-abc-treated-with-ribociclib-rib-fulvestrant-ful-a-subgroup-analysis-of-patients-with-invasive-lobular-carcinoma-ilc-<![CDATA[]]>Mon, 11 May 2026 22:30:00 GMTCancerNetworkusCancerNetwork Articles<![CDATA[What is the Future of TIL Therapy in Metastatic Melanoma? ]]>https://www.cancernetwork.com/view/what-is-the-future-of-til-therapy-in-metastatic-melanoma-https://www.cancernetwork.com/view/what-is-the-future-of-til-therapy-in-metastatic-melanoma-<![CDATA[Muhammad Umair Mushtaq, MD, discussed the evolution of TIL therapy in melanoma, focusing on first-line treatment potential and immune fitness.]]>Mon, 11 May 2026 19:00:00 GMTCancerNetworkusCancerNetwork Articles<![CDATA[Novel HP1K Inhibitor Shows Favorable Responses in ccRCC, Solid Tumors]]>https://www.cancernetwork.com/view/novel-hp1k-inhibitor-shows-favorable-responses-in-ccrcc-solid-tumorshttps://www.cancernetwork.com/view/novel-hp1k-inhibitor-shows-favorable-responses-in-ccrcc-solid-tumors<![CDATA[Grade 3 or higher TRAEs occurred in 14% of patients treated with NDI-101150, including 1 incidence of grade 4 aplastic anemia across all comers in the study.]]>Mon, 11 May 2026 17:00:00 GMTCancerNetworkusCancerNetwork Articles<![CDATA[FDA Grants RMAT Designation to RZ-001 in Advanced Hepatocellular Carcinoma]]>https://www.cancernetwork.com/view/fda-grants-rmat-designation-to-rz-001-in-advanced-hepatocellular-carcinomahttps://www.cancernetwork.com/view/fda-grants-rmat-designation-to-rz-001-in-advanced-hepatocellular-carcinoma<![CDATA[The FDA has granted RMAT designation to RZ-001, a first-in-class RNA trans-splicing ribozyme gene therapy, for the management of hepatocellular carcinoma.]]>Mon, 11 May 2026 15:22:51 GMTCancerNetworkusCancerNetwork Articles